Your Cart is Empty
Start shopping
MOUNJARO®
MOUNJARO® 7.5mg KwikPen®, 1 Stk. (English Alternative)
Note: Actual packaging may vary.
MOUNJARO® 7.5mg KwikPen®, 1 Stk. (English Alternative)
| Quantity | Discount (%) | Price |
|---|---|---|
| 1 - 3 | — | $519.00 |
| 4 - 10 | 11.56 % | $459.00 |
| 11 - 20 | 12.52 % | $454.00 |
| 21+ | 13.49 % | $449.00 |
MOUNJARO® is administered by subcutaneous injection once weekly, at any time of day, with or without food. Treatment begins at 2.5 mg once weekly for four weeks, followed by an increase to 5 mg. From there, further dose increases are made in 2.5 mg increments after a minimum of four weeks at the current dose, guided by the patient’s glycemic response and tolerability, up to a maximum of 15 mg per week.
The 7.5 mg English alternative sits in the titration pathway as the escalation step after 5 mg and before a potential increase to 10 mg. Patients who require continued titration may move to other MOUNJARO® KwikPen® doses under clinician guidance. For practices managing multiple patients across different stages, the structured 2.5 mg increment schedule allows clinicians to standardize follow-up intervals while adjusting individually.
Inject into the abdomen, thigh, or back of the upper arm, rotating the site with each dose. A missed dose may be administered within four days (96 hours) of the scheduled injection. After that window, skip the missed dose and resume the regular weekly schedule. If insulin is also prescribed, inject it at a separate site and do not mix the products.
MOUNJARO® contains tirzepatide, a dual GIP and GLP-1 receptor agonist. Approved indications vary by market, and practitioners should reference the prescribing information that accompanies the specific presentation they are using.
In the United States, MOUNJARO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Tirzepatide for chronic weight management is marketed in the U.S. under the separate brand name Zepbound®, so MOUNJARO® should not be described as FDA-approved for weight loss.
In India, tirzepatide falls under the oversight of the Central Drugs Standard Control Organisation (CDSCO), with the Drugs Controller General (India) serving as the Central Licensing Authority. Practitioners should not merge U.S. FDA labeling with CDSCO-approved labeling into a single indication statement. Instead, the product labeling and prescribing information supplied with the English alternative SKU should be treated as the authoritative reference for that market.
Professionals comparing tirzepatide weight management products should consider the approved indication and product labeling specific to their jurisdiction rather than treating all tirzepatide brands or presentations as interchangeable.
The active substance in the MOUNJARO® 7.5mg KwikPen English alternative is tirzepatide. Each dose delivers 7.5 mg in 0.6 mL, while the full pen contains 30 mg in 2.4 mL and provides four weekly doses.
Tirzepatide activates both GIP and GLP-1 receptors, influencing glucose-dependent insulin secretion, glucagon activity, gastric emptying, appetite, and energy intake. This dual-receptor mechanism distinguishes tirzepatide from single-incretin GLP-1 receptor agonists and is the basis for the clinical interest in blood sugar levels and weight management outcomes observed in the SURPASS and SURMOUNT trial programs.
The product is supplied as a multi-dose, single-patient-use pre-filled KwikPen. Pen needles are supplied separately. Clinicians and pharmacists or nurse staff responsible for administration should follow the manufacturer’s Instructions for Use accompanying the English alternative presentation.
English Alternative Packaging & International Availability
The MOUNJARO® 7.5mg KwikPen® (English Alternative) is an English-language packaging and presentation option distributed in selected international markets. “English alternative” is the Med Supply Solutions descriptor for this SKU and does not indicate a different active ingredient, dose, or mechanism of action. It should not be presented as a formal regulatory name used by national authorities.
India is one market where this KwikPen presentation is sold. The Central Drugs Standard Control Organisation (CDSCO), India’s national drug regulatory authority, reviewed Eli Lilly’s tirzepatide multiple-dose KwikPen through its Subject Expert Committee (Endocrinology & Metabolism) in 2024. The review specifically listed the 7.5 mg/0.6 mL strength among the proposed presentations. Reuters reported that Lilly received approval from India’s drug regulator for the once-weekly MOUNJARO® KwikPen in June 2025.
MOUNJARO® first entered India in late March 2025 in 2.5 mg and 5 mg vial presentations. The KwikPen launched later, in August 2025, in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
Clinics evaluating where to buy MOUNJARO® online typically weigh distributor credentials, documentation, and shipping conditions ahead of price alone. The English alternative KwikPen provides an internationally distributed presentation while retaining the same 7.5 mg tirzepatide dose per injection.
Storage
Storage instructions should be verified against the package leaflet supplied with the actual MOUNJARO® KwikPen 7.5mg (English Alternative) inventory. Refrigeration requirements, room-temperature limits, in-use duration, and discard timing may vary by market.
-
Check the pen: Confirm the medicine name, strength, expiration date, and solution clarity before each use.
-
Attach a new needle: Use a new compatible pen needle for every injection. Do not reuse needles.
-
Prime the pen: Prime as directed before administering the dose.
-
Select the dose: Use the dose knob to prepare the full fixed dose.
-
Inject: Administer subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites with each dose.
-
After use: Remove and safely discard the needle. Do not store the pen with a needle attached.
-
After four doses: Do not attempt to use any residual medicine left in the pen after the fourth full dose.
Practitioners looking to purchase MOUNJARO® KwikPen 7.5mg (English Alternative) online should verify that the accompanying Instructions for Use (IFU), storage requirements, and prescribing information are appropriate for their market and regulatory context before placing any order with a distributor.
Availability and Professional Inquiries
Practitioners who buy MOUNJARO® wholesale through authorized distributors should confirm that the product arrives with intact cold-chain documentation and verifiable LOT traceability. Shipping conditions are particularly relevant for this product class, since temperature excursions during transit can compromise the stability of tirzepatide solutions.
Licensed healthcare professionals seeking information about MOUNJARO® KwikPen 7.5mg (English Alternative) alternative wholesale pricing or availability may contact a member of the Med Supply Solutions team. We are available to assist with professional product inquiries and can provide details on the English alternative packaging currently in distribution.
MOUNJARO® is administered by subcutaneous injection once weekly, at any time of day, with or without food. Treatment begins at 2.5 mg once weekly for four weeks, followed by an increase to 5 mg. From there, further dose increases are made in 2.5 mg increments after a minimum of four weeks at the current dose, guided by the patient’s glycemic response and tolerability, up to a maximum of 15 mg per week.
The 7.5 mg English alternative sits in the titration pathway as the escalation step after 5 mg and before a potential increase to 10 mg. Patients who require continued titration may move to other MOUNJARO® KwikPen® doses under clinician guidance. For practices managing multiple patients across different stages, the structured 2.5 mg increment schedule allows clinicians to standardize follow-up intervals while adjusting individually.
Inject into the abdomen, thigh, or back of the upper arm, rotating the site with each dose. A missed dose may be administered within four days (96 hours) of the scheduled injection. After that window, skip the missed dose and resume the regular weekly schedule. If insulin is also prescribed, inject it at a separate site and do not mix the products.
MOUNJARO® contains tirzepatide, a dual GIP and GLP-1 receptor agonist. Approved indications vary by market, and practitioners should reference the prescribing information that accompanies the specific presentation they are using.
In the United States, MOUNJARO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Tirzepatide for chronic weight management is marketed in the U.S. under the separate brand name Zepbound®, so MOUNJARO® should not be described as FDA-approved for weight loss.
In India, tirzepatide falls under the oversight of the Central Drugs Standard Control Organisation (CDSCO), with the Drugs Controller General (India) serving as the Central Licensing Authority. Practitioners should not merge U.S. FDA labeling with CDSCO-approved labeling into a single indication statement. Instead, the product labeling and prescribing information supplied with the English alternative SKU should be treated as the authoritative reference for that market.
Professionals comparing tirzepatide weight management products should consider the approved indication and product labeling specific to their jurisdiction rather than treating all tirzepatide brands or presentations as interchangeable.
The active substance in the MOUNJARO® 7.5mg KwikPen English alternative is tirzepatide. Each dose delivers 7.5 mg in 0.6 mL, while the full pen contains 30 mg in 2.4 mL and provides four weekly doses.
Tirzepatide activates both GIP and GLP-1 receptors, influencing glucose-dependent insulin secretion, glucagon activity, gastric emptying, appetite, and energy intake. This dual-receptor mechanism distinguishes tirzepatide from single-incretin GLP-1 receptor agonists and is the basis for the clinical interest in blood sugar levels and weight management outcomes observed in the SURPASS and SURMOUNT trial programs.
The product is supplied as a multi-dose, single-patient-use pre-filled KwikPen. Pen needles are supplied separately. Clinicians and pharmacists or nurse staff responsible for administration should follow the manufacturer’s Instructions for Use accompanying the English alternative presentation.
English Alternative Packaging & International Availability
The MOUNJARO® 7.5mg KwikPen® (English Alternative) is an English-language packaging and presentation option distributed in selected international markets. “English alternative” is the Med Supply Solutions descriptor for this SKU and does not indicate a different active ingredient, dose, or mechanism of action. It should not be presented as a formal regulatory name used by national authorities.
India is one market where this KwikPen presentation is sold. The Central Drugs Standard Control Organisation (CDSCO), India’s national drug regulatory authority, reviewed Eli Lilly’s tirzepatide multiple-dose KwikPen through its Subject Expert Committee (Endocrinology & Metabolism) in 2024. The review specifically listed the 7.5 mg/0.6 mL strength among the proposed presentations. Reuters reported that Lilly received approval from India’s drug regulator for the once-weekly MOUNJARO® KwikPen in June 2025.
MOUNJARO® first entered India in late March 2025 in 2.5 mg and 5 mg vial presentations. The KwikPen launched later, in August 2025, in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
Clinics evaluating where to buy MOUNJARO® online typically weigh distributor credentials, documentation, and shipping conditions ahead of price alone. The English alternative KwikPen provides an internationally distributed presentation while retaining the same 7.5 mg tirzepatide dose per injection.
Storage
Storage instructions should be verified against the package leaflet supplied with the actual MOUNJARO® KwikPen 7.5mg (English Alternative) inventory. Refrigeration requirements, room-temperature limits, in-use duration, and discard timing may vary by market.
-
Check the pen: Confirm the medicine name, strength, expiration date, and solution clarity before each use.
-
Attach a new needle: Use a new compatible pen needle for every injection. Do not reuse needles.
-
Prime the pen: Prime as directed before administering the dose.
-
Select the dose: Use the dose knob to prepare the full fixed dose.
-
Inject: Administer subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites with each dose.
-
After use: Remove and safely discard the needle. Do not store the pen with a needle attached.
-
After four doses: Do not attempt to use any residual medicine left in the pen after the fourth full dose.
Practitioners looking to purchase MOUNJARO® KwikPen 7.5mg (English Alternative) online should verify that the accompanying Instructions for Use (IFU), storage requirements, and prescribing information are appropriate for their market and regulatory context before placing any order with a distributor.
Availability and Professional Inquiries
Practitioners who buy MOUNJARO® wholesale through authorized distributors should confirm that the product arrives with intact cold-chain documentation and verifiable LOT traceability. Shipping conditions are particularly relevant for this product class, since temperature excursions during transit can compromise the stability of tirzepatide solutions.
Licensed healthcare professionals seeking information about MOUNJARO® KwikPen 7.5mg (English Alternative) alternative wholesale pricing or availability may contact a member of the Med Supply Solutions team. We are available to assist with professional product inquiries and can provide details on the English alternative packaging currently in distribution.
Frequently Bought Together
About the product
MOUNJARO® 7.5mg KwikPen® (English Alternative) is a multi-dose, pre-filled pen containing tirzepatide, delivering 7.5 mg in each 0.6 mL weekly dose. Each pen provides four fixed weekly doses and serves as an escalation strength rather than the starting dose in the tirzepatide titration sequence. This English alternative presentation is also available in international markets such as India. Licensed healthcare professionals interested in the MOUNJARO® 7.5mg KwikPen® (English Alternative) may contact Med Supply Solutions for information on availability and wholesale pricing.